BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.

Sana Biotechnology raised $700 million in initial financing that will be used to advance the company’s discovery and development programs that create and deliver engineered cells as a treatment for different disease types.

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Nicholas Green has been appointed president and chief executive officer, as well as a member of the company’s board of directors, effective July 30,

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced its participation in the Noble Capital Markets c-suite webinar series. The webinar was led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D., with participation by Steven M. Fruchtman, M.D., President and

June 23, 2020 12:00 UTC ―Renibus Therapeutics Will Conduct Phase 2 Trial of Compound with Antiviral and Immune-Modulating Activity to treat effects of COVID-19 ― LOGAN, Utah--( BUSINESS WIRE )-- Frontier Scientific, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, today announced their collaboration with Renibus Therapuetics to develop a therapeutic for COVID-19. Frontier Scientific identified and developed mul

Companion Medical, manufacturers of InPen, the only FDA-cleared smart insulin pen system, today announced that they received FDA expanded clearance for all ages* to use the InPen System. “We are excited that we can help younger children and even more parents navigate the challenges associated with Type 1 diabetes. Now anyone can safe

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announced financial results for the fourth quarter and fiscal year 2020, ended March 31, 2020. Fiscal Year 2020 Cyanotech reported net sales of $31,899,000 for fiscal 2020 compared to $30,202,000 in fiscal 2019. Gross profit was $12,700,000, with gross profit margin of 39.8%,

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator - Dose-dependent reduction in circulating lymphocytes - - Rapid lymphocyte recovery after cessation of dosing - - Phase 2 study in ulcerative colitis patients in 4Q 2020 - ENCINITAS, Calif. and CAMBRIDGE, United Kingdom, June 23, 2020 (GLOBE NEWSWIRE) -- Oppilan Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment o

Geospark Analytics, the world class leader in developing applied artificial intelligence (AI) solutions for global threat and risk assessment, was just awarded a five-year, multi-million dollar contract with the U.S. Department of Health and Human Services (HHS) for use of the company’s Hyperion platform, its COVID-19 risk model, and development of new AI-driven disease outbreak models.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020 at 11:30am ET